Bispecific Antibodies – Quantifying Their Activity Using iLite® Bioassays
Newsletter

Bispecific Antibodies – Quantifying Their Activity Using iLite® Bioassays

Bispecific antibodies (BsAbs) are used to treat many conditions, and there is great hope that new antibody therapies will help in the treatment of many other diseases, including cancers, autoimmune disorders, and infectious diseases in the future. Find out more about BsAbs – what they are and how their activity can be quantified using cell-based reporter-gene assays.

The use of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of many disorders over the last decades and are increasingly used to treat common conditions such as cancer and autoimmune diseases.

However, mAbs can sometimes cause severe adverse effects as they commonly act on a systematic level, and may bind to non-target cells expressing the same antigen as the target, leading to a specificity problem.

One way of increasing the specificity of therapeutic antibodies is by using bispecific antibodies. First conceptualized in the 1960s, BsAbs have become promising therapeutic candidates for a number of disorders. However, it took almost 50 years for market approval of the first therapeutic BsAbs – a testament to the complexity of successfully developing these antibodies.

Download the white paper using the form and learn how BsAbs work, how they are useful, and how cell-based reporter-gene assays can be used as valuable tools in the development of new therapeutic BsAbs.

Fill in the form to access the free white paper